After hydroxychloroquine and vaccines, Cadila Healthcare Ltd., the flagship firm of India's Zydus Cadila group, has opened a new front to tackle COVID-19 and is working on filing an investigational new drug application in the US for the use of pegylated interferon alpha-2b to treat the disease.
The company said a study conducted by the University of Texas Branch and another by a group of universities in...






